Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15232697 | 0.87 | CTSS (0.46) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL28505550 | 0.87 | CTSS (0.46) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL25238924 | 0.85 | CTSS (0.50) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL15270465 | 0.85 | CTSS (0.50) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL27159106 | 0.85 | CTSS (0.50) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL25282758 | 0.84 | CTSS (0.49) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL23886560 | 0.84 | CTSS (0.49) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL21777294 | 0.84 | CTSS (0.49) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL265969 | 0.84 | CTSS (0.49) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL23886587 | 0.84 | CTSS (0.49) | CTSSCTSKPPARAPPARGATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582644-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-03-24 | — | — | US | disclosed |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2020047251-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047251-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-03-05 | — | — | WO | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-4108854-A | Process for preparing substituted glycines | SMITHKLINE CORPORATION (US) | 1978-08-22 | — | — | US | disclosed |
| US-3997584-A | Substituted glycines and intermediates thereof | SMITHKLINE CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3994954-A | Process for preparing substituted glycines | SMITHKLINE CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582644-B2 | O-GlcNAc transferase inhibitors and uses thereof | OGA, OGT, OSTC | CTSS 1495/4885CTSK 3504/4885PPARA 4249/4885 |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGT, OGA, UGGT1 | CTSS 897/4885CTSK 1546/4885PPARA 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.